Compare OGI & IPSC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | OGI | IPSC |
|---|---|---|
| Founded | 2013 | 2019 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medicinal Chemicals and Botanical Products |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 188.1M | 370.2M |
| IPO Year | 2015 | 2021 |
| Metric | OGI | IPSC |
|---|---|---|
| Price | $1.35 | $2.25 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $3.50 |
| AVG Volume (30 Days) | 396.7K | ★ 1.4M |
| Earning Date | 05-11-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 91.30 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $109,164,000.00 |
| Revenue This Year | $20.10 | N/A |
| Revenue Next Year | $13.92 | N/A |
| P/E Ratio | $13.91 | ★ N/A |
| Revenue Growth | N/A | ★ 1556.76 |
| 52 Week Low | $0.85 | $0.34 |
| 52 Week High | $2.24 | $2.97 |
| Indicator | OGI | IPSC |
|---|---|---|
| Relative Strength Index (RSI) | 47.01 | 51.51 |
| Support Level | $1.29 | $1.87 |
| Resistance Level | $1.73 | $2.68 |
| Average True Range (ATR) | 0.07 | 0.21 |
| MACD | 0.01 | -0.02 |
| Stochastic Oscillator | 63.16 | 46.60 |
Organigram Global Inc is a licensed cultivator of cannabis and manufacturer of cannabis-derived goods in Canada. It is is focused on producing high-quality cannabis for adult recreational consumers. It has also developed and acquired a portfolio of legal adult-use recreational cannabis brands, including Edison, Holy Mountain, Big Bag O' Buds, SHRED, SHRED'ems, Monjour, Tremblant Cannabis, Trailblazer, BOXHOT and DEBUNK. Organigram operates facilities in Moncton, New Brunswick and Lac-Superieur, Quebec, with a dedicated edibles manufacturing facility in Winnipeg, Manitoba.
Century Therapeutics Inc is a biotechnology company harnessing the power of allogeneic pluripotent stem cell therapies to develop potentially curative cell therapy products for autoimmune diseases, including type 1 diabetes, or T1D, and cancer. Its beta islet, T cell and NK cell programs are allogeneic, meaning it is derived from healthy donors for use in any patient, rather than being sourced from an individual for their own specific use, as is the case with autologous T cells. The cell types it can generate from iPSCs, including iPSC-derived beta islet cells, iPSC-derived CD4+ and CD8+ alphabeta T cells, or alphabeta iT cells, and iPSC- natural killer cells, or iNK cells.